arrow
Return

Genetic Code Expansion: Inception, Development, Commercialization

delete2021-03-23
delete58
PRE
AI
M
Miglena Manandhar
E
Eugene Chun
F
Floyd E. Romesberg *
DOI:10.1021/jacs.0c11938delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
Virtually all natural proteins are built from only 20 amino acids, and while this makes possible all the functions they perform, the ability to encode other amino acids selected for specific purposes promises to enable the discovery and production of proteins with novel functions, including therapeutic proteins with more optimal drug-like properties. The field of genetic code expansion (GCE) has for years enabled the production of such proteins for academic purposes and is now transitioning to commercialization for the production of more optimal protein therapeutics. Focusing on E. coli, we review the history and current state of the field. We also provide a review of the first generation commercialization efforts, the lessons learned, and how those lessons are guiding new efforts. With continued academic and industrial progress, GCE methodologies promise to make possible the routine optimization of proteins for therapeutic use in a way that has only previously been possible with small-molecule therapeutics.
Keywords:
TRANSFER-RNA SYNTHETASE
COLONY-STIMULATING FACTOR
UNNATURAL AMINO-ACIDS
IN-VIVO INCORPORATION
OCCURRING CLINICAL MASTITIS
SUPPRESSOR TRANSFER-RNAS
GROWTH-FACTOR 21
LEPTIN PEG-OB
SEMISYNTHETIC ORGANISM
ESCHERICHIA-COLI

Journal

Journal of the American Chemical Society cover
Journal of the American Chemical Society
IF:
15.6
Papers:
20.0W
Citations:
60.2W

Organization

No organization information available
Cited Papers

Cited Papers

Paraproteinemic neuropathy
err2009-09-15
err0
PREAI
errSaša A. Živković; David Lacomis; Suzanne Lentzsch
errShare
errSave
Example-Based Program Transformation
err2024-09-05
err0
PREAI
errRomain Robbes; Michele Lanza
errShare
errSave
errShare
errSave
A position statement on NAFLD/NASH based on the EASL 2009 special conference
err2010-08-01
err870
errOAAI
errRatziu, Vlad; Bellentani, Stefano; Cortez-Pinto, Helena; Day, Chris; Marchesini, Giulio
errShare
errSave
errShare
errSave
A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy
err2003-01-01
err509
errOAAI
errGreen, MD; Koelbl, H; Baselga, J; Galid, A; Guillem, V; Gascon, P; Siena, S; Lalisang, RI; Samonigg, H; Clemens, MR; Zani, V; Liang, BC; Renwick, J; Piccart, MJ
errShare
errSave
researcher View more